Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes factors involved in polycystic ovary syndrome pathogenesis and management, highlights commonly prescribed and repurposed medications, and calls for well-designed clinical trials to evaluate these treatments further.

In this study, the researchers developed a cellulose nanofiber-based scaffold containing sitagliptin and zinc sulfide nanoparticles, which promoted scarless healing and hair follicle regeneration in rats by targeting DPP4+ fibroblasts, suggesting a novel approach for improved wound healing and skin regeneration.

This book discusses the discovery and development of various drugs, including finasteride and statins, but reports no new research findings.

This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.

This chapter reviews pharmacodynamic evaluations in endocrine disorders focusing on oral antidiabetics, insulin analogues, and hormone interactions, but reports no new results.

The researchers designed a Janus microneedle system for treating vitiligo, which targets the skin’s layers to regulate the immune response, promote melanocyte regeneration, and enhance pigment transfer, offering a new precise treatment approach for this condition.

This letter discusses the potential of the Janus kinase 1 inhibitor abrocitinib for treating oral lichen planus but provides no new research findings.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This review discusses the approved uses and adverse reactions of JAK inhibitors, noting their importance in treating various conditions but highlighting significant hematological and immunological risks.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

This paper creatively examines whether the name "Janus" in Janus kinase inhibitors foreshadows their dual role in the treatment of dermatological conditions, drawing parallels to the Roman god Janus's dual nature and influence over beginnings and transitions.

This study found that a low-dose oral contraceptive containing dienogest provides effective contraception, improves cycle stability, and may reduce excessive scalp and skin oiliness, with high user satisfaction.

This systematic review found that Janus kinase inhibitors have shown beneficial effects for psoriasis and alopecia areata, with promising preliminary results in other skin conditions, though more research is needed to define dosing and safety profiles.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

This article reviews the mode of action, efficacy, and safety of Janus kinase inhibitors in autoimmune dermatological conditions but reports no new clinical results.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.

This study found that Janus kinase inhibitors were effective in inducing clinical and biochemical remission in patients with Ulcerative Colitis while exhibiting an expected safety profile, though 30% discontinued treatment due to adverse events or lack of efficacy.

This review covers the use of JAK inhibitors in treating various dermatological conditions, emphasizing their potential while noting ongoing safety concerns with oral treatments; no new clinical results are provided.

In this systematic review and meta-analysis on participants aged 12 and under with alopecia areata, the authors provide supplementary tables and figures, including pooled outcomes for hair regrowth and safety of oral Janus kinase inhibitors, supporting the main findings on their effectiveness and safety.

This article discusses Janus kinase inhibitors as a promising future treatment for alopecia areata but does not present new research findings.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

This article reviews non-biodegradable progestational subdermal implants as long-acting contraceptives for women, discussing their effectiveness, associated side effects, and implementation challenges without reporting new clinical results.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

No results are reported in this dataset abstract, which details supplementary materials for a systematic review and meta-analysis on oral Janus kinase inhibitors' effectiveness and safety in children with alopecia areata, aiming to enhance transparency and interpretation of the main article's findings.